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R adical cure of malaria, the elimination of both the blood and tissu e stages of the parasite s by chemotherapeutic agents, is desirab le for prevention of recurrence of infection after returning from w ork or travel in places where relapsing malaria is endemic. In studies that m easure attack rates of malaria, with or without chemoprophylactic intervention, radical cure is also necessary to elim inate interference and confounding by relapsin g or recrudescing parasitae mias. There is currently no single drug with suf® cient safety and dual blood and tissu e schizonticidal properties to achieve this steriliz ing cure. Most of our studies have used a combination of three drugs, quinine, doxycycline and prim aquine, to achieve radical cures (Jones et al., 1994; Fryauff et al., 1995;  C. J. Church, T . L. Richie, C. Ohrt, E. Tjitra, B. Subianto, B. Sandjaya, E. G om ez, J. K . Baird, D. J. Fryauff and A. L. Richards, unpubl. obs.; C. K . Ohrt, T . Richie, H . W idjaja, G . D. Shanks, D. J. Fryauff, E. T jitra, B. Sandjaja, H . Basri, W. W idjaja, C. Church and G . W att, unpubl. obs.). T he frequent, prolonged dosing of quinine and the undesirable side effects of this drug compound the problem of full com pliance with therapy. The drug-related illn ess which frequently occurs in otherwise healthy subjects discourages their voluntary partic ipation and, even am ong symptom atic cases, rigid supervision and incentives are required to achieve completion of therapy. T he doxycycline component is generally well-tolerated as long as it is not taken on an empty stom ach but, due to its effect on bone growth and tooth development, use of this drug is contra-in dicated in children under the age of 8 years and in females during pregnancy and nursing (Anon., 1995) . Despite the effectiveness of the current, quinine-based radical cure, there is interest in developing a m ore broadly acceptable drug regim en for radical cure of chloroquine-resistan t malaria.
Halofantrine is an effective and generally well-to lerated blood schizonticide for use against chloroquine-resistant Plasmodium falciparum in areas where m e¯oquine resistan ce has not also developed (H orton and Parr, 1989) . Trials have also demonstrate d this drug to be highly effective against P. vivax, including the chloroquine-resistant strain s occurrin g in Irian Jaya, Indonesia (Parkinson et al., 1989; Baird et al., 1995a) . The use of halofantrin e as an alternative component for achieving radical cure of malaria was therefore explored; the use of three, well tolerated doses of halofantrine over 12 h may be substantially better than treatment with 12 poorly tolerated doses of quinine over 4 days given concurrently with 20 doses of doxycycline over 10 days. T he aim of the present study was to see if falciparum and vivax m alaria acquired in Irian Jaya could be cured radically by using combined halofantrin e and prim aquine therapies. A`control' group, given sim ultaneous chloroquine and prim aquine therapies, was included in order to estim ate properly the effect of prim aquine on patency of parasitae mia after chloroquine therapeutic failu re.
PATIENTS AN D M ETHO DS

Study Site and Patients
The study was conducted in the new, transm igrant villages of Arso X and XI in northeastern Irian Jaya, Indonesia (Baird et al., 1995b; Fryauff et al., 1995) between January and July 1993. M ost of the approxim ately 2000 villagers had moved from Java, where the risk of m alaria infection has been about 1 case/10 000 person-years since 1965 (Baird et al., 1995c) . Point prevalences of m alaria at the tim e of enrolment were 24% in A rso X and 38% in Arso X I, despite the provision of bednets to all households and the availability of free chloroquine at the village health clinics.
Enrolm ent
Overall, 123 Javanese or Balinese males aged . 15 years, with uncomplicated malaria and parasitae mias of 0.001% ± 1.0% , quali® ed for enrolm ent. Informed consent, a physical examination and a negative qualitativ e test for glucose-6-phosphate dehydrogenase (NAD PH spot test; Sigm a) preceded their random assignm ent to one of two treatm ent groups: halofantrin e-prim aquine (H F-PQ ) or chloroquine-prim aquine (CQ-PQ ).
Treatm ent and Follow-up
Patients in the H F-PQ group received halofantrin e (a total of 24 m g base/kg bodyweight, in three equal doses over 12 h) and prim aquine (0.5 mg base/kg bodyweight daily for 14 days and thereafter on alternate days until day 28). Those in the C Q-PQ group were given chloroquine (a total of 25 m g base/kg bodyweight in three unequal doses over 48 h: 10 m g/kg on D ay 0; 10 m g/kg on Day 1; and 5 m g/kg on D ay 2) and prim aquine (as above). T hree drug formulatio ns were used: H alfan Ò (halofantrin e; 250 m g base hydrochloride salt in uncoated tablets, kindly provided by Dr J. Horton of SmithK line Beecham , Brentford, U .K .); prim aquine (15 mg base as diphosphate salt in coated tablets; Sano® -W inthrop, New York, N Y); and Resochin Ò (chloroquine; 150 m g base as phosphate salt in uncoated tablets; P. T . Bayer Indonesia, Jakarta). Every dose was supervised by a m ember of the research team. D ry biscuits and bottled water were provided and patients were encouraged to eat im mediately prior to or just after consum ing the m edication. Patients were visited in their homes daily for the ® rst 2 w eeks and then on alternate days until day 28. V isits consisted of adm inisterin g m edications, recording answers to a physicalcom plaint questionnaire, and making blood smears for parasitological examination. Patients sufferin g treatm ent failure were offered standard quinine therapy.
Parasitological Exam ination
D iagnosis of malaria was based upon microscopical exam ination of Giem sa-stain ed, thick and thin, blood ® lms using oil-im mersion optics ( 3 1000). At least 300 ocular ® elds w ere examined before a slid e was considered negative. The number of asexual parasite s per 200 white blood cells (W BC) was counted and the number of parasites/m l blood was then estim ated by multip lying this value by 40 (Shute, 1988) .
A nalysis of D ata
T he ef® cacy of combined HF-PQ therapies relativ e to that of combined CQ-PQ therapies was determ ined using Fisher' s exact test. The number of hours from startin g treatm ent to the point at which parasites became undetectable and rem ained so for at least 2 consecutive days constituted the parasiteclearance tim e (PCT). Axillary temperatures $ 37.5°C indicated fever and fever-clearance tim e (FCT) was the num ber of hours from startin g treatm ent to the point at which a normal tem perature of at least two consecutive days' duration began. One-w ay analysis of variance was used to compare age, weight, density of parasitae mia, PCT, frequency of fever and FCT between the two treatm ent groups. T he incidence density (ID) of physical complaints not associated with parasitaem ia was calculated from the number of complaints reported per person-m onth of observation after discounting day-0 complaints and those associated with unrem ittin g or recurrent parasitae mias. The decline of all physical complaints, including those associated with the initial parasitae mias, was estim ated from the proportion of patients reporting any complaint consisten t with m alaria (fever, chills, headache, malaise , abdom inal pain, nausea, vom itin g, diarrh oea, arthralgia, myalgia) and the incidence density per person-day of speci® c complaints reported on each of test days 0± 7. Proportion s and incidence densitie s were compared using Fisher' s exact test or c 2 with Yate' s correction applied. Two-taile d P values are reported and the cut-off for statistica l signi® cance was a P value # 0.05.
RESU LT S
B aseline Characteristics
There were no statistic ally signi® cant diffe rences between treatm ent groups at enrolment in terms of m ean age, weight or parasitaemia (Table 1) . M ore than 92% of the study patients in each treatm ent group presented with m alarial sym ptoms at enrolm ent and the tw o treatm ent groups were sim ilar in the num ber and types of physical complaints reported (Fig. 1) . M alaise, headache, abdominal pain and nausea were the most frequently reported physical complaints. Fever w as observed in 50% (35/70) of the P. falciparum cases and in 49% (26/53) of the P. vivax.
Com parative Ef® cacy
H F-PQ was completely effective and no treatm ent failures (persisten t or recurrent parasitaem ias) occurred among the 40 P. falciparum and 26 P. vivax cases during 28 days of follow-up (100% ef® cacy). In contrast,
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TA BLE 1
Baseline characteristics of study patients random ized to halofantrine-primaquine (HF -PQ) or chloroquine-prim aquine (CQ -PQ ) treatm ent groups
Plasm odium falciparum 28 (8) 31 (10) 27 (8) 33 (9) M ean (S.D.) weight (kg) 50 (7) 51 (7) 51 (7) 49 ( F ig. 1. Proportions of subjects w ith malaria-related physical complaints after treatment with halofantrine-prim aquine (h ) or chloroquine-prim aquine (6 ) and mean numbers of physical complaints after treatment with halofantrine-prim aquine (Ð ) or chloroquine-prim aquine (± ± ± ) amongst the P. falciparum (a) and P. vivax (b) cases.
failures of CQ-PQ therapy occurred within 28 days in 20 of the 30 patients infected with P. falciparum (33% ef® cacy) and in three of the 27 patients infected with P. vivax (89% ef® cacy). HF-PQ was signi® cantly more ef® cacious than CQ-PQ against P. falciparum (P , 0.001) but sim ilarly ef® cacious against P. vivax (P 5 0.23). As expected, CQ-PQ was signi® cantly more ef® cacious against P. vivax than against P. falciparum (P , 0.001).
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T ABL E 2 T he means (and ranges) Clearance of Parasitaem ia and Fever T here was no difference in PCT between the two treatm ent regim ens for either P. falciparum (P 5 0.61) or P. vivax (P 5 0.44). U nder either regim en or infection, the m ean PCT was about 50 h (Table 2 ). In contrast, FCT in malaria cases treated with H F-PQ was a mean of 17 h shorter than in those given CQ -PQ and the diffe rence was signi® cant for both P. falcipa rum (P 5 0.003) and P. vivax (P 5 0.008).
Physical Com plaints
In the absence of a patent parasitaemia, physical complaints in both treatm ent groups w ere infrequent, but the ID per person-week of m alaria-like complaints during the follow-up period was consiste ntly lower among patients treated with HF-PQ and collectively w ere reported 3.7± 4.0 tim es less often than by cases of falciparum and vivax m alaria treated with CQ -PQ (P , 0.005; Fig. 2 ). Figure 1 shows a compariso n of the interval (daily) proportions of patients registering any physical com plaint consisten t with m alaria and the ID/person-day of these speci® c malarial com plaints during test days 0± 7, between treatment groups for each m alaria species. D ay-0 physical complaints were sim ilar in the two treatm ent groups and m ost com plaints were registe red during the ® rst 48 h of evaluation, before and during the period of parasite clearance. W ithin 24 h of having received the last HF-PQ dose, there was a highly signi® cant decline in the proportion of patients reportin g any physical complaint (P 5 0.003 for P. falciparum; P 5 0.02 for P. vivax) and in the number of speci® c complaints reported by a patient (P , 0.001 for P. falciparum ; P 5 0.005 for P. vivax). In contrast, CQ-PQ treatm ent required 48± 72 h to produce a statistic ally signi® cant reduction in physical complaints.
DISCUSSION
The rationale for the prim aquine dosing used in the present study was that cure of P. vivax of New G uinea-Irian Jaya origin requires 0.5 m g/kg rather than the standard regim en of 0.25 mg/kg (Clyde and M cCarthy, 1977) . The unconventional, alternate-day dosing of 0.5 m g/kg following the 14-day therapy period was applied as causal prophylaxis, to prevent re-infection and/or relapse while not interferin g with recrudescence (Arnold et al., 1954 (Arnold et al., , 1955 Schmidt et al., 1982; W ernsdorfer and Payne, 1988) . It is recognized, however, that chloroquine and prim aquine do apparently act synergistically against P. vivax (Baird et al., 1995a) . Alternate-day use of prim aquine, alone, at 0.5 mg base/kg has been shown to be a well tolerated prophylactic regimen, afford ing protective ef® cacies of 74% against P. falciparum and 90% against P. vivax among non-im mune children and adults living in Irian Jaya (Baird et al., 1995b) .
Com bined HF-PQ therapy cleared parasitaem ia from all of the study patients and no treatm ent failu res occurred w ithin 28 days of beginning treatm ent, in cases of uncom plicated falciparum or vivax m alaria acquired in north-eastern Irian Jaya. This regimen apparently provided a 100% ef® cacious radical cure. The therapeutic failure s seen am ong sim ilar patients treated with CQ-PQ prove this because it shows that prim aquine, per se, was not suf® cient to prevent the appearance of bloodstage parasite s. The absence of recurrent parasitaem ias am ong patients treated w ith HF-PQ therefore demonstrates complete clearance of the asexual blood stages of P. falciparum and P. vivax. These results accord w ith those of another study in which treatment of P. vivax with chloroquine or halofantrine, alone, was com pared in the sam e location in Irian Jaya (Baird et al., 1995a) . In that study, just one of 19 patients treated with halofantrine had a recurrence of parasitaemia and this single infection, which appeared 25 days post-therapy, was considered to have been a re-infection or relapse. Subsequent, more extensive use of halofantrin e alone against P. falciparum or of halofantrin e with prim aquine against P. vivax in the Arso district of Irian Jaya has achieved com parably high success rates (A. Richards and T. Richie, unpubl. obs.). A clinical trial of halofantrin e alone in East Kalim antan, Indonesia, achieved a cure rate for uncomplicated falciparum malaria of . 98% (T jitra et al., 1992) , with FCT and PCT sim ilar to those seen in the present study when halofantrine and prim aquine were used together. Physical complaints reported in the absence of detectable parasitaemias were consisten tly higher among patients treated with CQ-PQ than in those given HF-PQ, but these complaints may not have been drug-related. Although there were no diffe rences between treatment groups in PCT, the slower decline of malaria-like illness seen in cases treated with CQ-PQ , and certainly the high failu re rate obtained with this combination against P. falciparum, indicate that the physical complaints were related more to subpatent parasitaem ias in the non-im m une populatio n sam pled than to side effects of the drugs.
Prim aquine administe red at a single daily dose of 0.5 mg base/kg for 14 days apparently clears the liver of the tissu e stages of P. falciparum and P. vivax. Although the present results do not prove this, the results of other studies demonstrate this effect. The adult regim en of 30 m g daily for 14 days was completely effective against the C hesson strain of P. vivax from New Guinea, whereas the 15-m g regim en has been repeatedly unsuccessfu l (Clyde and M cCarthy, 1977; R om bo et al., 1987; Jelinek et al., 1995) . In a series of four trials conducted in the Arso region of Irian Jaya between 1993 and 1995, a total of 651 study volunteers, m ost of them non-im m une to m alaria, and . 25% with patent malaria infections, were cured radically with a com bination of quinine, doxycycline and prim aquine (Q4D10P14) and no subsequent chemoprophylaxis. N ot one of these subjects developed a patent parasitaemia within 2 weeks of the end of the 14-day therapy (Jones et al., 1994; Fryauff et al., 1995 ). H ad any parasitae mia appeared within the usual 8± 14-day incubation period, this would have marked the failu re of prim aquine to clear the liver. Extrapolating from the results for the study populations involved (N 5 651) and assuming a conservative tw o m alaria infections/person-year for the Arso region, an expected 50 parasitaemias w ould have appeared within the collective 50 personyears of post-rad ical-cure susceptibility which were contributed by these 651 volunteers if prim aquine had not been an effective causal prophylactic. The absence of any such parasitaem ia is a con® rmation of prim aquine' s potent effect on the liver stages of falciparum and vivax m alaria when dosed at 0.5 m g base/ kg daily for 14 days. Parasitaemias following the 14-day prim aquine regimen, as applied with halofantrine in the current study, could only have resulted from re-infections.
Reports of cardiotoxicity associated w ith the high-dose halofantrine regimen (Castot et al., 1993; N osten et al., 1993) and changes in recommendations for its use (W HO , 1993) were only publish ed after the completion of the present study. W hile the administrati on of halofantrin e with food is now contra-ind icated, the provision of food in this study was intended to protect against the stomach upsets associated with prim aquine use (Clayman et al., 1952; C lyde, 1981) . It now seems clear that foods m ay have enhanced the bio-availability and perhaps the ef® cacy of halofantrin e in the present study (Shanks et al., 1992) .
In sum mary, combined halofantrin e and prim aquine therapies achieved radical cure of falciparum and vivax malaria among nonimm une, G 6PD-normal, Indonesian men. The H F-PQ regim en was associated with signi® cantly fewer occasions of physical complaint and/or drug intolerance than were experienced by patients randomized to CQ-PQ therapy, and a more rapid decline of malaria symptom s. T hese results indicate that the H F-PQ regim en m ay be preferred over quinine-doxycycline-prim aquine for radical cure of m alaria am ong G6PD-norm al men with no contra-in dicating, cardiac risk factors.
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